a/s:

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue…

5 days ago

Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them

Company announcement no. 32 In accordance with Article 19 (3) of the Market Abuse Regulation, Columbus A/S is required to…

3 months ago

Coloplast A/S – Announcement no. 07/2025 – Coloplast announces new financial ambition towards 2030

In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue…

5 months ago

Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…

6 months ago

NTG Nordic Transport Group A/S – H1 2025 Conference Call

July 14, 2025 02:00 ET  | Source: NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S – H1 2025…

7 months ago

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

8 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

8 months ago